

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 May 2001 (17.05.2001)

PCT

(10) International Publication Number  
WO 01/34598 A1

(51) International Patent Classification<sup>7</sup>: C07D 403/08,  
A61K 31/404, A61P 25/24

(74) Agents: ECK, Steven, R.; American Home Products Corporation, Patent Law Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 et al. (US).

(21) International Application Number: PCT/US00/29954

(22) International Filing Date: 31 October 2000 (31.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/436,119 8 November 1999 (08.11.1999) US

(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors: ASSELIN, Magda; 64 Ackerman Drive, Mahwah, NJ 07430 (US). ELLINGBOE, John, Watson; 117 John Street, Ridgewood, NJ 07450 (US). MEWSHAW, Richard, Eric; Apartment B-509, 251 West Dekalb Pike, King of Prussia, PA 19406 (US).

(54) Title: [(INDOL-3-YL)-CYCLOALKYL]-3-SUBSTITUTED AZETIDINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS



(57) Abstract: This invention provides novel compounds and pharmaceutical compositions and methods of using the compounds in the treatment of central nervous system disorders, such as anxiety and depression, the compounds having formula (I), wherein: X is N-R, O, S(O)<sub>m</sub>; m is 0 to 2; n is 0 to 4; Ar is an aryl group of 6 to 12 carbon atoms optionally substituted with 1 to 3 R<sub>3</sub> groups, or a heteroaryl group of 4 to 10 carbon atoms optionally substituted with 1 to 3 R<sub>3</sub> groups; R and R<sub>2</sub> are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkoxycarbonyl of 1 to 6 carbon atoms, alkylcarbonyl of 1 to 6 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms; R<sub>1</sub> and R<sub>3</sub> are independently H, straight chain alkyl of 1 to 4 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, halo, alkoxy group of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, OH, nitro, amino, sulfonyl, CN, carboxy, alkoxycarbonyl of 1 to 4 carbon atoms, alkylcarbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms; and all crystalline forms or a pharmaceutically acceptable salt thereof.

WO 01/34598 A1

- 1 -

5     **[(INDOL-3-YL)-CYCLOALKYL]-3-SUBSTITUTED AZETIDINES FOR THE  
TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS**

**Field of the Invention**

10           This invention relates to new N-(indolyl-cycloalkyl) azetidine derivatives which are useful as pharmaceuticals for the treatment of diseases caused by disorders of the serotonin-affected neurological systems, such as depression and anxiety.

**Background of the Invention**


15           Pharmaceuticals which enhance serotonergic neurotransmission are useful for the treatment of many psychiatric disorders, including depression and anxiety. The first generation of non-selective serotonin-affecting drugs operated through a variety of physiological functions which endowed them with several side-effect liabilities.

20           The more currently prescribed drugs, the selective serotonin (5-HT) reuptake inhibitors (SSRIs), act predominately by inhibiting 5-HT, which is released at the synapses, from being actively removed from the synaptic cleft via a presynaptic serotonin transport carrier.

25           The present invention relates to a new class of molecules which have the ability to act at the 5-HT transporter. Such compounds are therefore potentially useful for the treatment of depression as well as other serotonin disorders.

Described in WO 95/20588 are compounds of general formula:

- 2 -



5


Wherein R and  $R_1$  are each independently hydrogen or  $C_{1-4}$  alkyl, or R and  $R_1$  are linked to form an azetidine ring. These compounds are reported to have activity at the  $5HT_1$  receptor and be useful for the treatment of migraine, headache and

10 headache associated with vascular disorder.

### Summary of the Invention

In accordance with this invention there is provided a group of compounds

15 represented by the formula I:



wherein:

- X is N-R, O,  $S(O)_m$ ;
- 20 m is an integer of 0 to 2;
- n is an integer of 0 to 4;
- Ar is an aryl group of 6 to 12 carbon atoms optionally substituted with 1 to 3 groups selected independently from  $R_3$ ,  $R_4$  and  $R_5$ , or a heteroaryl group of 4 to 10

- 3 -

5 carbon atoms optionally substituted with 1 to 3 selected independently from  $R_3$ ,  $R_4$  and  $R_5$ ;

$R$  and  $R_2$  are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkoxy carbonyl of 1 to 6 carbon atoms, alkyl carbonyl of 1 to 6 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms;

$R_1$ ,  $R_3$ ,  $R_4$  and  $R_5$  are independently H, straight chain alkyl of 1 to 4 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, halogen, alkoxy group of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, hydroxy, nitro, amino, sulfonyl, cyano, carboxy, alkoxy carbonyl of 1 to 4 carbon atoms, alkyl carbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms;

and all crystalline forms or a pharmaceutically acceptable salt thereof.

20

In a preferred aspect of this invention are provided compounds of formula I wherein:

X is O, or NR;

n is an integer of 0 to 1;

25 Ar is an aryl group of 6 to 10 carbon atoms optionally substituted with 1 to 3 groups selected independently from  $R_3$ ,  $R_4$  and  $R_5$ , or a heteroaryl group of 5 to 10 carbon atoms optionally substituted with 1 to 3 groups selected independently from  $R_3$ ,  $R_4$  and  $R_5$ ;

30  $R$  and  $R_2$  are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, or cycloalkyl of 3 to 6 carbon atoms;

- 4 -

5            $R_1$ ,  $R_3$ ,  $R_4$  and  $R_5$  are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, halogen, alkoxy of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, hydroxy, nitro, nitrile, amino, sulfonyl, cyano, carboxy, alkoxycarbonyl of 1 to 4 carbon atoms, alkylcarbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4  
10 carbon atoms;

and all crystalline forms or a pharmaceutically acceptable salt thereof.

In another preferred group of compounds of this invention:

15            $X$  is  $S(O)_m$ ;

$m$  is an integer of 0 to 2;

$n$  is an integer of 0 or 1;

$Ar$  is an aryl group of 6 to 10 carbon atoms optionally substituted with 1 to 3 groups selected independently from  $R_3$ ,  $R_4$  and  $R_5$ , or a heteroaryl group of 5 to 10  
20 carbon atoms optionally substituted with 1 to 3 groups selected independently from  $R_3$ ,  $R_4$  and  $R_5$ ;

$R$  and  $R_2$  are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, or cycloalkyl of 3 to 6 carbon atoms;

25

$R_1$ ,  $R_3$ ,  $R_4$  and  $R_5$  are independently selected from H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, halogen, alkoxy of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, hydroxy, nitro, nitrile, amino, sulfonyl, cyano, carboxy, alkoxycarbonyl of 1 to 4  
30 carbon atoms, alkylcarbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms;

- 5 -

5 and all crystalline forms or a pharmaceutically acceptable salt thereof.

A subset of these preferred compounds includes those in which X is  $S(O)_m$ ; m is an integer from 0 to 2; and Ar is a phenyl ring optionally substituted by from 1 to 3 groups independently selected from  $R_3$ ,  $R_4$  and  $R_5$ , defined above.

10

Aryl, as used herein refers to single or multiple 6 to 12 membered aromatic ring radicals including but not limited to phenyl, naphthalene, anthracene, phenanthrene, indene and indacene, in some embodiments of the present invention, the aryl group may be substituted with one to three groups selected from  $R_3$ ,  $R_4$  and  $R_5$ .

15

Heteroaryl as used herein refers to single or multiple 5 to 10 membered aromatic ring radicals having from 1 to 3 hetero atoms independently selected from nitrogen, oxygen and sulfur, including, but not limited to, furan, thiophene, pyrrole, imidazole, oxazole, thiazole, isoxazole, pyrazole, isothiazole, oxadiazole, triazole, thiadiazole, quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, naphthyridine, pteridine, pyridine, pyrazine, pyrimidine, pyridazine, pyran, triazine, indole, isoindole, indazole, indolizine, and isobenzofuran. In some embodiments of the present invention, the heteroaryl group is substituted with one to three groups selected from those of  $R_3$ ,  $R_4$  and  $R_5$ .

20

Alkyl, whether used alone or as part of another group includes straight and branched chain alkyl groups containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, *i*-butyl and *t*-butyl are encompassed by the term alkyl. In alkyl-containing groups herein, such as alkylcarbonyl and alkylaminocarbonyl groups, the number of carbon atoms listed refers to the alkyl group, itself, and not including the carbonyl carbon. In some embodiments of the

30

- 6 -

5 present invention alkyl may refer to substituted or unsubstituted alkyl. The substituted alkyl groups in these compounds may be fully substituted, such as with perhalogenated compounds. Other alkyl groups in these definitions may be substituted by from 1 to 3 substituents selected from halogen, hydroxy, CN, NO<sub>2</sub>, or NH<sub>2</sub>. The number of carbon number refers to carbon backbone and does not include  
10 carbon atoms of substituents such as alkoxy substitutions and the like.

Halogen is preferably fluoro, chloro, bromo or iodo.

Among the most preferred compounds of the present invention are:

15

{ 1-[cis-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl)-2-methoxy-phenyl  
)amine;

20

{ 1-[trans-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl)-2-methoxy-phenyl)  
amine;

3-{ cis-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole-5 carbonitrile;

25

3-{ trans-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole-5-  
carbonitrile;

2-{ cis-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole-5-  
carbonitrile;

30

2-{ trans-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole-5-;

- 7 -

- 5 { 1-[cis-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl}-(3-fluoro-phenyl)-  
amine;
- { 1-[cis-4-(1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl}-(2-methoxy-phenyl)-amine;
- 10 { 1-[trans-4-(1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl}-(2-methoxy-phenyl)-amine;
- 2-{ cis-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole;
- 2-{ trans-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole;
- 15 5-fluoro-3-{ cis-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole ;
- 5-fluoro-3-{ trans-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole ;
- 20 5-fluoro-3-{ cis-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole;
- 5-fluoro-3-{ trans-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole;
- 3-{ cis-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole;
- 25 3-{ trans-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole;
- 6-fluoro-3-{ cis-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H- indole;
- 30 6-fluoro-3-{ trans-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H- indol;
- or a pharmaceutically acceptable salt of one or more of these compounds.



- 8 -

5

It is understood that the definition of the compounds of formula I, when R, R<sub>1</sub>, R<sub>2</sub> or R<sub>3</sub> contain asymmetric carbons, encompass all possible stereoisomers and mixtures thereof which possess the activity discussed below. In particular, it encompasses racemic modifications and any optical isomers which possess the indicated activity. Optical isomers may be obtained in pure form by standard separation techniques.

Pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: lactic, citric, acetic, tartaric, succinic, maleic, malonic, oxalic, fumaric, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids. Where R, R<sub>1</sub>, R<sub>2</sub> or R<sub>3</sub> contain a carboxyl group, salts of the compounds of this invention may be formed with bases such as alkali metals (Na, K, Li) or the alkaline earth metals (Ca or Mg).

As mentioned previously, the compounds of formula I have been found to have affinity for the 5-HT reuptake transporter. They are therefore useful in the treatment of diseases affected by disorders of the serotonin affected neurological systems, such as depression, anxiety, sleep disorders, sexual dysfunction, alcohol and cocaine addiction, cognition enhancement and related problems. The present invention accordingly provides methods of treatment or prevention of these maladies, the methods comprising administering to a mammal, preferably a human, in need thereof pharmaceutically effective amount of a compound of this invention, or a pharmaceutically acceptable salt thereof.

This invention also provides pharmaceutical compositions which comprise one or more compounds of this invention, or a pharmaceutically acceptable salt thereof, in combination or association with one or more pharmaceutically acceptable

- 9 -

5 carriers or excipients. The compositions are preferably adapted for oral or subcutaneous administration. However, they may be adapted for other modes of administration.

10 The compositions of the invention may be formulated with conventional excipients, such as a filler, a disintegrating agent, a binder, a lubricant, a flavoring agent and the like. They are formulated in conventional manner, for example, in a manner similar to that use for known antihypertensive agents, diuretics and  $\beta$ -blocking agents.

15 Applicable solid carriers or excipients can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is  
20 mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose,  
25 polyvinylpyrrolidone, low melting waxes and ion exchange resins.

Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic  
30 solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents,

- 10 -

5 thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols e.g. glycols) and their derivatives, and oils (e.g. fractionated  
10 coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

Liquid pharmaceutical compositions which are sterile solutions or suspensions  
15 can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.

Preferably the pharmaceutical composition is in unit dosage form, e.g. as  
20 tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions  
25 in package form.

In order to obtain consistency of administration, it is preferred that a composition of the invention is in the form of a pharmaceutically effective unit dose. Suitable unit dose forms include tablets, capsules and powders in sachets or vials.  
30 Such unit dose forms may contain from 0.1 to 100 mg of a compound of the invention and preferably from 2 to 50 mg. Still further preferred unit dosage forms contain 5 to 25 mg of a compound of the present invention. The compounds of the

- 11 -

- 5 present invention can be administered orally at a dose range of about 0.01 to 100 mg/kg or preferably at a dose range of 0.1 to 10 mg/kg. Such compositions may be administered from 1 to 6 times a day, more usually from 1 to 4 times a day.


10 The following specific examples illustrate the synthetic procedures for the preparation of intermediates and invention compounds and should not be construed as limiting the scope of this disclosure. Those skilled in the art of organic synthesis may be aware of still other routes to prepare compounds of this invention. Reactants and intermediates are either commercially available or can be prepared according to standard literature procedures.

15

In accordance with the present invention, compounds of formula I may be prepared by Scheme I

- 12 -

## Scheme I




5

Thus, a compound of formula (2) is reacted with a compound of formula (3) in the presence of a reducing reagent such as sodium triacetoxyborohydride, and acetic acid in a solvent such as dichloroethane at  $23^\circ\text{C}$  to give a compound of formula I in accordance with the procedure described by Abdel-Magid, Carson, Harris, Maryanoff and Shah in *J. Org. Chem.* 1996, 61, 3849.

In accordance with the present invention, compounds of formula (3) may be prepared by Scheme II.

- 13 -


## Scheme II



- Thus a compound of formula (4) is reacted with 1,4-cyclohexanedione monoethylene ketal, potassium hydroxide in methanol at 65 °C to give compounds of formula (5) as described by Wustrow *et al.* in *J. Med. Chem.* **1997**, *40*, 250.
- 10 Hydrogenation to a compound of formula (6) can be realized by treatment in suitable solvents such as an alcohol, but not limited to ethanol with  $H_2$  and 5% Pd/C. Hydrolysis to a compound of formula (3) can be carried out using 1N HCl in a 1:1 mixture of THF and water.

- 14 -

- 5 In accordance with the present invention, compounds of formula (2) may be prepared by Scheme III.

**Scheme III**

10


Thus, a compound of formula (7) is prepared by reaction of N-benzhydryl-3-hydroxyazetidine with methanesulfonyl chloride and triethylamine in a solvent such as dichloromethane. Compound (7) is reacted with a compound of formula (9) in the

- 15 -

5 presence of a base such as potassium carbonate in a solvent such as acetonitrile to yield a compound of formula (8). Deprotection of the azetidine nitrogen with ammonium formate in an alcoholic solvent such as methanol yields a compound of formula (2).

10 Compounds of formula (2) where X is NR are prepared according to scheme IV. Standard N-alkylation methods may be used to convert a compound of formula (9) where R is hydrogen to a compound of formula (9) where R is alkyl.

### Scheme IV





- 16 -

5

While the reaction schemes above show intermediates substituted only by R<sub>3</sub> groups, the presence of optional R<sub>4</sub> and R<sub>5</sub> groups in these compounds is understood.

10 The present invention further provides a compound of the invention for use as an active therapeutic substance. Compounds of formula I are of particular use in the treatment of diseases affected by disorders of the serotonin.

15 The present invention further provides a method of treating depression and anxiety in mammals including man, which comprises administering to the afflicted mammal an effective amount of a compound or a pharmaceutical composition of the invention.

The following examples are presented to illustrate rather than limit the present invention.

20

- 17 -

## 5 Examples

The 5-HT transporter affinity of the compounds of this invention was established in accordance with standard pharmaceutically accepted test procedures with representative compounds as follows:

10

### Rat Brain <sup>3</sup>H-Paroxetine Binding Assay (RB 5HT Transporter):

The following assay was used to determine a compound's affinity for the 5-HT transporter.

15

A protocol similar to that used by Cheetham *et. al.* (*Neuropharmacol.* **1993**, 32, 737) was used. Briefly, frontal cortical membranes prepared from male S.D. rats were incubated with <sup>3</sup>H-paroxetine (0.1 nM) for 60 min. at 25 °C. All tubes also contained either vehicle, test compound (one to eight concentrations), or a saturating  
20 concentration of fluoxetine (10 μM) to define specific binding. All reactions are terminated by the addition of ice cold Tris buffer followed by rapid filtration using a Tom Tech filtration device to separate bound from free <sup>3</sup>H-paroxetine. Bound radioactivity was quantitated using a Wallac 1205 Beta Plate<sup>®</sup> counter. Nonlinear regression analysis was used to determine IC<sub>50</sub> values which were converted to K<sub>i</sub>  
25 values using the method of Cheng and Prusoff (*Biochem. Pharmacol.* **1973**, 22, 3099):

30

$$K_i = \frac{IC_{50}}{\text{Radioligand concentration}/(1+KD)}$$

- 18 -

5 Inhibition of  $^3\text{H}$ -5-HT Uptake by cells Possessing the Human 5-HT Transporter (HC 5HT Transporter):

A human carcinoma cell line (Jar cells) possessing low endogenous levels of the 5-HT-transporter are seeded into 96 well plates and treated with staurosporine at  
10 least 18 h prior to assay. [Staurosporine greatly increases the expression of the 5-HT-transporter.] On the day of assay, vehicle, excess of fluoxetine, or test compound is added to various wells on the plate. All wells then receive  $^3\text{H}$ -5-HT and are incubated at 37 °C for 5 min. The wells are then washed with ice cold 50 mM Tris HCl (pH 7.4) buffer and aspirated to remove free  $^3\text{H}$ -5-HT. 25  $\mu\text{l}$  of 0.25 M NaOH is then  
15 added to each well to lyse the cells and 75  $\mu\text{l}$  scintillation cocktail (Microscint™ 20) added prior to quantitation on a Packard TopCount machine. Tubes with vehicle represent total possible uptake, radioactivity counted in tubes with fluoxetine represent nonspecific binding/uptake and is subtracted from the total possible uptake to give total possible specific uptake. This nonspecific binding (usual low in number)  
20 is then subtracted from the counts obtained in wells with various test compounds (or different concentrations of test drug) to give specific uptake in the presence of drug. Specific uptake is then expressed as a % of control values and is analyzed using nonlinear regression analysis (Prizm) to determine  $\text{IC}_{50}$  values. If the compound is active at inhibiting 5-HT uptake, its counts will be close to that obtained with  
25 fluoxetine.

Results from these two assays are presented below in Table I.

- 19 -

5

**Table I**


Compound	n	RB 5HT Transporter	HC 5HT Transporter
		K <sub>i</sub> (nM)	IC <sub>50</sub> (nM)
Example 1a	1	15.0	962
Example 1b	1	17.0	591
Example 2a	1	16.0	336.50
Example 2b	1	48.0	282
Example 3a	1	2.38	91
Example 3b	1	11.0	232
Example 4	1	18.0	6390
Example 5a	1	124	-
Example 5b	1	34.0	-
Example 6a	1	120.0	-
Example 6b	1	-	-
Example 7a	1	257	-
Example 7b	1	68	6000
Example 8a	1	24.0	6000
Example 8b	1	45.0	1500
Example 9a	1	275.0	-
Example 9b	1	455.0	-
Example 10a	1	190	-
Example 10b	1	73	4600

- 20 -

5

**Example 1a**

**{1-[cis-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl}-2-methoxy-phenyl)-  
amine**

**Step 1**

10

**4-(5-Fluoro-1H-3-indolyl)-cyclohex-3-ene-ethylene ketal**

5-Fluorindole (4.96, 0.036 mol), 1,4-cyclohexanedione monoethylene ketal (7.17 g, 0.046 mol) and potassium hydroxide (6 g, 0.043 mol) were heated to reflux in 70 mL of methanol for 6 h. The reaction was cooled and the product was isolated by filtration and washed with water to give 8.59 g (86%) of product as a white solid: mp 153-155°C.

**Step 2****4-(5-Fluoro-1H-3-indolyl)-cyclohexanone ethylene ketal**

20

A mixture of 4-(5-fluoro-1H-3-indolyl)-cyclohex-3-en-ethylene ketal (8.5 g) and 10% palladium on carbon (2.72 g) in ethanol (200 mL) was hydrogenated for 5 h. The catalyst was filtered off and the solvent was removed under vacuum. Chromatography (methanol-methylene chloride) afforded 7.55 g (82 %) of product as a white solid: mp 183-185°C.

25

- 21 -

5

**Step 3****4-(5-Fluoro-1H-3-indolyl)-cyclohexanone**

A solution of 4-(5-fluoro-1H-3-indolyl)-cyclohexanone ethylene ketal (2.8 g, 10 mmol) in 2 L of 1:1 tetrahydrofuran-hydrochloric acid (1N) was allowed to stir at room temperature for 16 h. The solvent was evaporated under vacuum. The crude product was dissolved in ethyl acetate, washed with 1N sodium hydroxide (3 x 150 mL). The organic layer was dried over anhydrous sodium sulfate, and filtered. Chromatography (40% ethyl acetate/hexanes) afforded 2.1 g (91%) of product as a yellow solid: mp 112-114°C.

15

**Step 4****1-(Diphenylmethyl)-3-methane sulfonyl azetidine**

To a cold solution of 34 g (0.142 mol) of 1-(diphenylmethyl)-3-hydroxyazetidine in 200 mL of  $\text{CH}_2\text{Cl}_2$  was added 30 mL (212 mmol) of triethylamine. To the cold mixture a solution of 19.5 g (0.171 mol) of methanesulfonyl chloride in 50 mL of  $\text{CH}_2\text{Cl}_2$  was added dropwise. The reaction was stirred at room temperature for 2 h. Water was added and the methylene chloride was removed under vacuo. The product was extracted with ether, the combined extracts were dried over anhydrous sodium sulfate, and filtered to yield 36 g of product.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  2.98 (s, 3H), 3.21 (m, 2H), 3.66 (m, 2H), 4.39 (s, 3H), 5.10 (m, 1H), 7.22 (m, 2H), 7.27 (m, 4H), 7.38 (m, 4H).

- 22 -

5

**Step 5****(1-Benzhydryl-azetidin-3-yl)-(2-methoxy-phenyl)-amine**

To a solution of 4.1 g (0.033 mol) of o-anisidine in 20 mL DMF, 4.6 g (0.033 mol) of  $K_2CO_3$  was added, followed by 9.5g (0.030 mol) of 1-(diphenylmethyl)-3-methane sulfonyl azetidine. The reaction was heated at 80 °C for 5 h. Water was added and the product was extracted with ether. The organic phase was dried and the solvent was removed under vacuo. The residue was filtered through silica gel, starting with 100% methylene chloride, then 25% ethyl acetate/hexane to give 1.5 g of the desired product: mp 75-77 °C.  $^1H$  NMR (300 MHz,  $CDCl_3$ )  $\delta$  2.89 (dd, 2H), 3.70 (dd, 2H), 3.84 (s, 3H), 4.13 (m, 1H), 4.40 (m, 1H), 4.38 (s, 1H), 6.42 (dd, 1H), 6.69 (dd, 1H), 6.79 (m, 2H), 7.20 (m, 2H), 7.26 (m, 4H), 7.42 (m, 4H); MS (ES) m/z (relative intensity): 345 ( $M^+ + H$ ).

15

Elemental analysis for  $C_{23}H_{24}N_2O$

Calculated: C, 80.20; H, 7.02; N, 8.13

20

Found: C, 80.53; H, 7.17; N, 8.13.

**Step 6****Azetidin-3-yl-(2-methoxy-phenyl)-amine**

A solution of 2.0 g of (1-benzhydryl-azetidin-3-yl)-(2-methoxyphenyl)-amine in 30 mL of methanol was added to a suspension of 10% Pd/C in methanol. 4.0 g of ammonium formate was added portion wise and the reaction was heated under reflux for 2 h. The mixture was cooled, filtered over celite, the filtrate was evaporated. The residue was triturated with  $CH_2Cl_2$ , and filtered. The filtrate was evaporated to give 0.840 g of the desired product.

25

30


- 23 -

5

**Step 7****{1-[cis-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl}-2-methoxy-phenyl)-amine**

To a solution of 0.170 g of (1-benzhydryl-azetidin-3-yl)-(2-methoxy-phenyl)-  
10 amine in 10 mL of  $\text{CH}_2\text{Cl}_2$ , was added 4-(5-fluoro-1-H-3-indolyl)-cyclohexanone  
followed by 0.420 g of sodium triacetoxyborohydride. The reaction was stirred at  
room temperature overnight. It was quenched with 1N NaOH, and the product was  
extracted with ether. The organic phase was washed with water and dried over  
magnesium sulfate. The product was filtered through 150 mL of silica gel using 50%  
15 ethyl acetate/hexanes, 75% ethyl acetate/hexanes, and finally 100% ethyl acetate to  
give 0.150 g of the desired product: mp 158-160 °C.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$   
1.50-1.94 (m, 8H), 2.28 (m, 1H), 2.84-2.90 (m, 2H), 3.80-3.85 (m, 5H), 4.08-4.14  
(m, 1H), 4.38 (m, 1H), 6.51-6.68 (dd, 1H), 6.69-6.91 (m, 4H), 7.07 (d, 1H), 7.24-  
7.28 (m, 2H), 8.02 (s, 1H); MS (ES)  $m/z$  (relative intensity): 394 ( $\text{M}^+ + \text{H}$ ).

20

**Example 1b****{1-[trans-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl}-2-methoxy-phenyl)-amine**

25




- 24 -

5           The trans isomer of the compound of Example 1a was isolated at the same time as the cis isomer as an off white solid (0.045 g): mp 73-76 °C. MS (ES) m/z (relative intensity): 394 (M<sup>+</sup>+H).

**Example 2a**

10           **3-(cis-4-[3-(3-Fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl)-1H-indole-5-carbonitrile**

**Step 1**

**4-(5-Cyano-1H-3-indolyl)-cyclohex-3-ene-ethylene ketal**

15

The title compound was prepared according to the procedure of Example 1a, Step 1 except that 5-cyanoindole was used in place of 5-fluoroindole. Yield: 50%; mp 158-160 °C.

**Step 2**

**4-(5-Cyano-1H-3-indolyl)-cyclohexanone ethylene ketal**

20

The title compound was prepared according to the procedure of Example 1a, Step 2, using 4-(5-cyano-1H-3-indolyl)-cyclohex-3-ene-ethylene ketal. Yield: 95%;  
25 mp 153-155 °C.

- 25 -

5

**Step 3****3-(4-Oxo-cyclohexyl)-1H-indole-5-carbonitrile**

The title compound was prepared according to the procedure of Example 1,  
10 Step 3, except that 4-(5-cyano-1H-3-indolyl)-cyclohexanone ethylene ketal was used.  
Yield: 81%; mp 162-164 °C.

**Step 4****1-Benzhydryl- 3-(3-Fluoro-phenoxy)-azetidine**

15

To a solution of 3.9 g (0.035 mol) of 3-fluorophenol in 250 mL of  
acetonitrile, was added 6.3 g (0.045 mol) of  $K_2CO_3$  followed by 12.25 g (0.039 mol)  
of 1-(diphenylmethyl)-3-methane sulfonyl azetidine, prepared according to the  
procedure of Example 1a, Step 4. The reaction mixture was heated at 75 °C for 18 h.  
20 The solvent was removed under vacuo, and the residue was taken up in a mixture of  
ether and water. The aqueous layer was extracted with ether, the combined extracts  
were dried over magnesium sulfate, and the solvent was removed under vacuo. The  
product was filtered through 500 mL of silica gel, eluted with 50%  $CH_2Cl_2$ /hexane  
then 15% ethyl acetate/hexane to give 3.4 g of the title compound: mp 81-82 °C.  $^1H$   
25 NMR (300 MHz,  $CDCl_3$ )  $\delta$  3.17 (dd, 2H), 3.72 (dd, 2H), 4.46 (s, 1H), 4.77 (m, 1H),  
6.48 (dd, 1H), 6.53 (dd, 1H), 6.63 (m, 1H), 7.22 (m, 3H), 7.29 (m, 4H), 7.31 (dd,  
4H); MS (ES) m/z (relative intensity): 334 ( $M^+ + H$ ).

- 26 -

5

**Step 6****3-(3-Fluoro-phenoxy)-azetidine**

A solution of 2.50 g of 1-benzhydryl-3-(3-fluoro-phenoxy)-azetidine in 10 mL of THF was added to a suspension of 10% Pd/C in methanol. Ammonium formate (4.6g) were added portion wise and the reaction was heated under reflux for 10 3 h. The mixture was cooled, filtered through celite, and the filtrate was concentrated. The residue was triturated with CH<sub>2</sub>Cl<sub>2</sub> and filtered. The filtrate was concentrated to give 0.840 g of the desired product.

15

**Step 7****3-(cis-4-[3-(3-Fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl)-1H-indole-5-carbonitrile**

To a solution of 0.170 g of 3-(3-fluoro-phenoxy)-azetidine in 10 mL of CH<sub>2</sub>Cl<sub>2</sub> was added 0.180 g of 3-(4-oxo-cyclohexyl)-1H-indole-5-carbonitrile followed by 0.420 g of sodium triacetoxyborohydride. The reaction was stirred at room temperature overnight. It was quenched with 1N NaOH and the product was extracted with ether. The organic phase was washed with water, dried over magnesium sulfate, filtered, and concentrated. The product was filtered through 150 25 mL of silica gel using 50% ethyl acetate/hexane, 75% ethyl acetate/hexane and finally 100% ethyl acetate to give 0.095 g of the desired product: mp 187-190 °C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.51-1.65 (m, 2H), 1.69-1.75 (m, 4H), 1.77-1.90 (m, 2H), 2.45 (m, 1H), 2.90 (m, 1H), 3.03 (dd, 2H), 3.81 (dd, 2H), 4.77 (m, 1H), 6.53-6.59 (m, 2H), 6.66 (m, 1H), 7.13-7.22 (m, 2H), 7.39 (dd, 2H), 8.00 (s, 1H), 8.28 (s, 1H); MS 30 (ES) m/z (relative intensity): 390 (M<sup>+</sup>+H).


Elemental analysis for C<sub>24</sub>H<sub>24</sub>FN<sub>3</sub>O

- 27 -

5           Calculated: C, 74.01; H, 6.21; N, 10.79  
          Found: C, 73.95; H, 6.24; N, 10.45.

**Example 2b**

10           **3-(trans-4-[3-(3-Fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl)-1H-indole-5-**  
          **carbonitrile**




15           The trans isomer of the compound of Example 2a was isolated at the same  
          time as the cis isomer as a white solid (0.037 g): mp 186-192 °C. <sup>1</sup>H NMR (300  
          MHz, CDCl<sub>3</sub>) δ 1.98-1.33 (m, 2H), 1.45-1.49 (m, 2H), 1.95-1.99 (m, 2H), 2.14-2.23  
          (m, 3H), 2.73-2.83 (m, 1H), 3.17 (dd, 2H), 3.89 (dd, 2H), 4.78 (m, 1H), 6.48-6.70 (m,  
          3H), 7.06 (d, 1H), 7.18-7.24 (m, 2H), 7.40 (dd, 2H), 8.00 (s, 1H), 8.23 (s, 1H); MS  
          (ES) m/z (relative intensity): 390 (M<sup>+</sup>+H).

- 28 -

5

**Example 3a**

**2-{cis-4-[3-(3-Methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole-5-carbonitrile**




10

The title compound was prepared according to the procedure of Example 2a, using m-methoxy-phenol in Step 5, and 3-(4-oxo-cyclohexyl)-1H-indole-5-carbonitrile in Step 7. mp 126-127 °C. MS (ES) m/z (relative intensity): 402 (M<sup>+</sup>+H).

15

**Example 3b**

**2-{trans-4-[3-(3-Methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole-5-carbonitrile**



- 29 -


5

The trans isomer of the compound of Example 3a was isolated at the same time as the cis isomer as a white solid (0.055g ): mp 58-62 °C. MS (ES) m/z (relative intensity): 402 ( $M^+ + H$ ).

10

**Example 4**

**{1-[cis-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl}-(3-fluoro-phenyl)-amine**




The title compound was prepared according to the procedure of Example 1a, Step 5 using m-fluoroaniline: mp 67-70 °C. MS (ES) m/z (relative intensity): 382 ( $M^+ + H$ ).

15


- 30 -

5

**Example 5a****{1-[cis-4-(1H-Indol-3-yl)-cyclohexyl]-azetidin-3-yl}-(2-methoxy-phenyl)-amine**

The title compound was prepared according to the procedure of Example 1a, using 3-(4-oxo-cyclohexyl)-1H-indole in Step 7: mp 67-70 °C. MS (ES) m/z (relative intensity): 382 ( $M^+ + H$ ).

10


**Example 5b****{1-[trans-4-(1H-Indol-3-yl)-cyclohexyl]-azetidin-3-yl}-(2-methoxy-phenyl)-amine**

15

The trans isomer of the compound of Example 5a was isolated at the same time as the cis isomer as an off white solid (0.045 g): mp 73-76 °C. MS (ES) m/z (relative intensity): 394 ( $M^+ + H$ ).

- 31 -

5

**Example 6a****2-{cis-4-[3-(3-Methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole**


The title compound was prepared according to the procedure of Example 2a, using m-methoxy-phenol in Step 5, and 3-(4-oxo-cyclohexyl)-1H-indole in Step 7:  
10 mp 126-127 °C. MS (ES) m/z (relative intensity): 383 (M<sup>+</sup>+H).

Elemental analysis for C<sub>23</sub>H<sub>24</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>

Calculated: C, 72.23; H, 6.33; N, 7.32

Found: C, 72.43; H, 5.88; N, 7.07.

15

**Example 6b****2-{trans-4-[3-(3-Methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole**




- 32 -

- 5           The trans isomer of the compound of Example 6a was isolated at the same time as the cis isomer as an off white solid: mp 52-57 °C. MS (ES) m/z (relative intensity): 383 ( $M^+ + H$ ).

**Example 7a**


- 10       **5-Fluoro-3-{cis-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole**



- The title compound was prepared according to the procedure of Example 2a, Step 7 using 4-(5-fluoro-1H-3-indolyl)-cyclohexanone: mp 119-125 °C. MS (ES)  
15   m/z (relative intensity): 383 ( $M^+ + H$ ).


- 33 -

5

**Example 7b****5-Fluoro-3-{trans-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole**

The trans isomer of the compound of Example 7a was isolated at the same time as the cis isomer as an off white solid: mp 52-57 °C. MS (ES) m/z (relative intensity): 395 ( $M^+ + H$ ).

10

**Example 8a****5-Fluoro-3-{cis-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole**

15


The title compound was prepared according to the procedure of Example 2a, using m-methoxy-phenol in Step 5, and 4-(5-fluoro-1H-3-indolyl)-cyclohexanone in Step 7: mp 125-127 °C. MS (ES) m/z (relative intensity): 395 ( $M^+ + H$ ).

- 34 -

5

**Example 8b**

**5-Fluoro-3-{trans-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole**



The trans isomer of the compound of Example 8a was isolated at the same  
10 time as the cis isomer as a white solid (0.055 g): mp 59-63 °C. MS (ES) m/z  
(relative intensity): 395 ( $M^+ + H$ ).

Elemental analysis for  $C_{24}H_{27}FN_2O_2$


Calculated: C, 73.07; H, 6.90; N, 7.10

Found: C, 72.98; H, 7.32; N, 6.51.

15

**Example 9a**

**3-{4-[3-(3-Fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole**




- 35 -

- 5           The title compound was prepared according to the procedure of Example 2a, using 3-(4-oxo-cyclohexyl)-1H-indole in Step 7: mp 114-117 °C. MS (ES) m/z (relative intensity): 365 ( $M^+ + H$ ).

**Example 9b**


- 10           **3-{4-[3-(3-Fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole**



- The trans isomer of the compound of Example 9a was isolated at the same time as the cis isomer as a white solid (0.055 g): mp 146-148 °C. MS (ES) m/z (relative intensity): 365 ( $M^+ + H$ ).
- 15

**Example 10a**

- 6-Fluoro-3-{4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole**



- 36 -

5           The title compound was prepared according to the procedure of Example 2a, using 4-(5-fluoro-1H-3-indolyl)-cyclohexanone in step 7: mp 117-123 °C. MS (ES) m/z (relative intensity): 383 (M<sup>+</sup>+H).


Elemental analysis for C<sub>23</sub>H<sub>24</sub>F<sub>2</sub>NO

Calculated: C, 72.23; H, 6.33; N, 7.32

10           Found: C, 72.19; H, 6.49; N, 7.13.

#### Example 10b

#### 6-Fluoro-3-{4-[3-(3-fluorophenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole




15

The trans isomer of the compound of Example 10a was isolated at the same time as the cis isomer as a white solid: mp 111-114 °C. MS (ES) m/z (relative intensity): 383 (M<sup>+</sup>+H).

20

#### Example 11

#### N-methyl o-Anisidine




- 37 -

5           A solution of 12.3 g of o-anisidine in 50 mL of ethyl formate was heated under reflux for 6 h. Excess ethyl formate was removed under vacuo. The residue was washed with ether to give 10.0 g of N-formyl o-anisidine.

          To a cold solution of 9.0 g of N-formyl o-anisidine in 50 mL of THF was added 66 mL of a 1M solution of LAH in THF dropwise at 0 °C. After complete  
10 addition the reaction mixture was stirred at 0 °C for one h. The reaction was then quenched with ethyl acetate, then with a saturated solution of  $\text{NH}_4\text{Cl}$ . The mixture was extracted with ether, the combined extracts were dried over magnesium sulfate, and the solvent was removed to give 6.0 g of product.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  2.85 (s, 3H), 3.83 (s, 3H), 4.16 (s, 1H), 6.61 (dd, 1H), 6.69 (m, 1H), 6.75 (dd, 1H),  
15 6.87 (m, 1H).

### Example 12

#### (1-Benzhydryl-azetidin-3-yl)-(2-methoxy-phenyl)-methyl-amine



20

          To a solution of 0.65 g of N-methyl o-anisidine in 15 mL of acetonitrile, was added 0.280g of  $\text{K}_2\text{CO}_3$ , followed by 0.650g of 1-(diphenylmethyl)-3-methane sulfonyl azetidine. The reaction mixture was heated at 80 °C for 1 h then at 50 °C overnight. Water was added and the mixture was extracted with ether. The organic  
25 phase was dried and the solvent was removed under vacuo. The product was filtered through 100 mL of silica gel, eluting with 15% ethyl acetate/hexanes then 25% ethyl

- 38 -

- 5 acetate/hexanes to give 0.200 g of the desired product: mp 91-95 °C. MS (ES) m/z (relative intensity): 356 ( $M^+ + H$ ).

Elemental analysis for  $C_{24}H_{26}N_2O$


Calculated: C, 80.41; H, 7.31; N, 7.81

Found: C, 80.57; H, 7.39; N, 7.69.

- 39 -

## 5 What is Claimed:

1. A compound of the formula:



wherein:

- 10 X is N-R, O, S(O)<sub>m</sub>;  
m is an integer of 0 to 2;  
n is an integer of 0 to 4;

Ar is an aryl group of 6 to 12 carbon atoms optionally substituted with 1 to 3 groups selected independently from R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>, or a heteroaryl group of 4 to 10 carbon atoms optionally substituted with 1 to 3 groups selected independently from R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>;

15

R and R<sub>2</sub> are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkoxy carbonyl of 1 to 6 carbon atoms, alkyl carbonyl of 1 to 6 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms;

20

R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently H, straight chain alkyl of 1 to 4 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, halogen, alkoxy group of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, hydroxy, nitro, amino, sulfonyl, cyano, carboxy, alkoxy carbonyl of 1 to 4 carbon

25



- 40 -

5 atoms, alkylcarbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms;

and all crystalline forms or a pharmaceutically acceptable salt thereof.

2. A compound of Claim 1 wherein:

10 X is O, or NR;

n is an integer of 0 to 1;

Ar is an aryl group of 6 to 10 carbon atoms optionally substituted with 1 to 3 groups selected independently from R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>, or a heteroaryl group of 5 to 10 carbon atoms optionally substituted with 1 to 3 groups selected independently from

15 R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>;

R and R<sub>2</sub> are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, or cycloalkyl of 3 to 6 carbon atoms;

20 R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, halogen, alkoxy of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, hydroxy, nitro, nitrile, amino, sulfonyl, cyano, carboxy, alkoxycarbonyl of 1 to 4 carbon atoms, alkylcarbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4  
25 carbon atoms;

or a pharmaceutically acceptable salt thereof.

3. A compound of Claim 1 wherein:

30 X is S(O)<sub>m</sub>;

m is an integer of 0 to 2;

n is an integer of 0 to 1;

- 41 -

5           Ar is an aryl group of 6 to 10 carbon atoms optionally substituted with 1 to 3 groups selected independently from R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>, or a heteroaryl group of 5 to 10 carbon atoms optionally substituted with 1 to 3 groups selected independently from R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>;

10           R and R<sub>2</sub> are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, or cycloalkyl of 3 to 6 carbon atoms;

          R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms,  
15       halogen, alkoxy of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, hydroxy, nitro, nitrile, amino, sulfonyl, cyano, carboxy, alkoxy carbonyl of 1 to 4 carbon atoms, alkyl carbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms;

20       or a pharmaceutically acceptable salt thereof.

          4.     A compound of Claim 1 which is {1-[cis-4-(5-Fluoro-1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl)-2-methoxy-phenyl }amine; or a pharmaceutically acceptable salt thereof.

25

          5.     A compound of Claim 1 which is {1-[trans-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl)-2-methoxy-phenyl }amine; or a pharmaceutically acceptable salt thereof.

30

          6.     A compound of Claim 1 which is 3-{cis-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole-5 carbonitrile; or a pharmaceutically acceptable salt thereof.

5

7. A compound of Claim 1 which is 3-{trans-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole-5-carbonitrile; or a pharmaceutically acceptable salt thereof.

10

8. A compound of Claim 1 which is 2-{cis-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole-5-carbonitrile; or a pharmaceutically acceptable salt thereof.

15

9. A compound of Claim 1 which is 2-{trans-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole-5-; or a pharmaceutically acceptable salt thereof.

20

10. A compound of Claim 1 which is {1-[cis-4-(5-fluoro-1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl}-(3-fluoro-phenyl)-amine; or a pharmaceutically acceptable salt thereof.

25

11. A compound of Claim 1 which is {1-[cis-4-(1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl}-(2-methoxy-phenyl)-amine; or a pharmaceutically acceptable salt thereof.

30

12. A compound of Claim 1 which is {1-[trans-4-(1H-indol-3-yl)-cyclohexyl]-azetidin-3-yl}-(2-methoxy-phenyl)-amine; or a pharmaceutically acceptable salt thereof.

13. A compound of Claim 1 which is 2-{cis-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole; or a pharmaceutically acceptable salt thereof.

5           14.    A compound of Claim 1 which is 2-{trans-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole; or a pharmaceutically acceptable salt thereof.

            15.    A compound of Claim 1 which is 5-fluoro-3-{cis-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole; or a pharmaceutically acceptable salt  
10   thereof.

            16.    A compound of Claim 1 which is 5-fluoro-3-{trans-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole; or a pharmaceutically acceptable salt  
15   thereof.

            17.    A compound of Claim 1 which is 5-fluoro-3-{cis-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole; or a pharmaceutically acceptable salt  
          thereof.

20           18.    A compound of Claim 1 which is 5-fluoro-3-{trans-4-[3-(3-methoxy-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole;

            19.    A compound of Claim 1 which is 3-{cis-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole; or a pharmaceutically acceptable salt thereof.  
25


            20.    A compound of Claim 1 which is 3-{trans-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole; or a pharmaceutically acceptable salt thereof.

            21.    A compound of Claim 1 which is 6-fluoro-3-{cis-4-[3-(3-fluoro-phenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indole; or a pharmaceutically acceptable  
30   salt thereof.

- 44 -

22. A compound of Claim 1 which is 6-fluoro-3-{trans-4-[3-(3-fluorophenoxy)-azetidin-1-yl]-cyclohexyl}-1H-indol; or a pharmaceutically acceptable salt thereof.

23. A compound of the formula:



wherein:

- X is N-R, O, S(O)<sub>m</sub>;  
 m is an integer of 0 to 2;  
 n is an integer of 0 to 4;  
 R and R<sub>2</sub> are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkoxy carbonyl of 1 to 6 carbon atoms, alkyl carbonyl of 1 to 6 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms;  
 R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently H, straight chain alkyl of 1 to 4 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, halogen, alkoxy group of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, hydroxy, nitro, amino, sulfonyl, cyano, carboxy, alkoxy carbonyl of 1 to 4 carbon atoms, alkyl carbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms;  
 and all crystalline forms or a pharmaceutically acceptable salt thereof.

- 45 -

5           24.     A compound of Claim 22 wherein:

          X is N-R or O;

          n is an integer of 0 to 4;

          R and R<sub>2</sub> are independently H, straight chain alkyl of 1 to 6 carbon atoms,  
          branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms,  
10       alkoxycarbonyl of 1 to 6 carbon atoms, alkylcarbonyl of 1 to 6 carbon atoms,  
          aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms;

          R<sub>1</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently H, straight chain alkyl of 1 to 4 carbon  
          atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms,  
          halogen, alkoxy group of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms,  
15       hydroxy, nitro, amino, sulfonyl, cyano, carboxy, alkoxycarbonyl of 1 to 4 carbon  
          atoms, alkylcarbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl  
          of 1 to 4 carbon atoms;

          and all crystalline forms or a pharmaceutically acceptable salt thereof.

20           25.     A compound of Claim 23 wherein:

          X is N-R;

          R is H, straight chain alkyl of 1 to 4 carbon atoms or branched alkyl of 3 to 6  
          carbon atoms; and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are as defined in Claim 23;

          and all crystalline forms or a pharmaceutically acceptable salt thereof.

25

          26.     A method of treating anxiety in a mammal, the method comprising  
          administering to a mammal in need thereof a pharmaceutically effective amount of a  
          compound of Claim 1, or a pharmaceutically acceptable salt thereof.

30           27.     A method of treating depression in a mammal, the method comprising  
          administering to a mammal in need thereof a pharmaceutically effective amount of a  
          compound of Claim 1, or a pharmaceutically acceptable salt thereof.

- 46 -

5

28. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

10

29. A compound as claimed in any one of claims 1-24 for use in treating anxiety or depression.

15

30. The use of a compound as claimed in any one of claims 1-24 for the manufacture of a medicament for the treatment of anxiety or depression.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/29954

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07D403/08 A61K31/404 A61P25/24

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 51576 A (AMERICAN HOME PROD) 14 October 1999 (1999-10-14) claims	1-30
A	WO 95 20588 A (WELLCOME FOUND ; GLEN ROBERT CHARLES (GB); FOSTER CHRISTOPHER JAMES) 3 August 1995 (1995-08-03) cited in the application claims	1-30
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

8 February 2001

Date of mailing of the international search report

16/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Chouly, J



# INTERNATIONAL SEARCH REPORT

Inter national Application No  
PCT/US 00/29954

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WUSTROW D J ET AL:  "3-(4-ARYL-1-PIPERAZINYL)ALKYLCYCLOHEXYL-1  H-INDOLES AS DOPAMINE D2 PARTIAL AGONISTS  AND AUTORECEPTOR AGONISTS"  JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN  CHEMICAL SOCIETY. WASHINGTON, US,  vol. 40, no. 2, 1997, pages 250-259,  XP000960706  ISSN: 0022-2623  the whole document</p>	1-30
P, A	<p>WO 00 40554 A (AMERICAN HOME PROD)  13 July 2000 (2000-07-13)  claims</p>	1-30

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 00/29954

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9951576 A	14-10-1999	AU 3386299 A EP 1068184 A	25-10-1999 17-01-2001
WO 9520588 A	03-08-1995	AP 632 A AU 689195 B AU 1462095 A AU 6348998 A BG 100747 A BR 9506581 A CA 2181475 A CN 1143960 A CZ 9602169 A EP 0741725 A FI 962969 A HU 76288 A IL 112443 A JP 9512248 T NO 963117 A NZ 278644 A PL 315666 A SG 44926 A SK 96796 A US 5922748 A US 6103752 A US 5744466 A ZA 9500601 A	30-03-1998 26-03-1998 15-08-1995 18-06-1998 31-03-1997 23-09-1997 03-08-1995 26-02-1997 11-06-1997 13-11-1996 25-07-1996 28-07-1997 27-12-1998 09-12-1997 23-09-1996 26-02-1998 25-11-1996 19-12-1997 04-06-1997 13-07-1999 15-08-2000 28-04-1998 25-07-1996
WO 0040554 A	13-07-2000	AU 2490900 A	24-07-2000